SBIO vs. PBE
SBIO (ALPS Medical Breakthroughs ETF) and PBE (Invesco Dynamic Biotechnology & Genome ETF) are both Health & Biotech Equities funds - SBIO tracks the S-Network Medical Breakthroughs Index while PBE tracks the Dynamic Biotech & Genome Intellidex Index (AMEX). Both are passively managed. Over the past 10 years, SBIO returned 7.86%/yr vs 7.34%/yr for PBE. Their correlation of 0.86 suggests significant overlap in exposure. SBIO charges 0.50%/yr vs 0.59%/yr for PBE.
Performance
SBIO vs. PBE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SBIO achieves a -1.78% return, which is significantly lower than PBE's -1.43% return. Over the past 10 years, SBIO has outperformed PBE with an annualized return of 7.86%, while PBE has yielded a comparatively lower 7.34% annualized return.
SBIO
- 1D
- -4.73%
- 1M
- -6.02%
- YTD
- -1.78%
- 6M
- 5.47%
- 1Y
- 67.29%
- 3Y*
- 17.25%
- 5Y*
- 2.56%
- 10Y*
- 7.86%
PBE
- 1D
- -2.22%
- 1M
- 1.51%
- YTD
- -1.43%
- 6M
- -0.16%
- 1Y
- 28.65%
- 3Y*
- 9.70%
- 5Y*
- 2.89%
- 10Y*
- 7.34%
SBIO vs. PBE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SBIO ALPS Medical Breakthroughs ETF | -1.78% | 55.07% | 3.81% | 8.68% | -28.08% | -17.55% | 21.17% | 50.30% | -11.81% | 45.67% |
PBE Invesco Dynamic Biotechnology & Genome ETF | -1.43% | 24.84% | 1.10% | 3.71% | -10.83% | 1.54% | 25.66% | 18.65% | -0.19% | 22.28% |
Correlation
The correlation between SBIO and PBE is 0.70, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.70 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.77 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.81 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.84 |
Correlation (All Time) Calculated using the full available price history since Jan 2, 2015 | 0.86 |
The correlation between SBIO and PBE shifts across timeframes, from 0.70 (1 year) to 0.86 (all time), reflecting how their relationship changes across market environments.
SBIO vs. PBE - Sectors Allocation Comparison
Sectors
SBIO
PBE
Healthcare
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Industrials
-
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Financial Services
Healthcare
SBIO
PBE
Basic Materials
SBIO
-
PBE
-
Communication Services
SBIO
-
PBE
-
Consumer Cyclical
SBIO
-
PBE
-
Consumer Defensive
SBIO
-
PBE
-
Energy
SBIO
-
PBE
-
Industrials
SBIO
-
PBE
-
Real Estate
SBIO
-
PBE
-
Technology
SBIO
-
PBE
-
Utilities
SBIO
-
PBE
-
Financial Services
SBIO
PBE
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SBIO vs. PBE — Risk / Return Rank
SBIO
PBE
SBIO vs. PBE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ALPS Medical Breakthroughs ETF (SBIO) and Invesco Dynamic Biotechnology & Genome ETF (PBE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| SBIO | PBE | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.30 | 1.55 | +0.75 |
Sortino ratioReturn per unit of downside risk | 3.17 | 2.33 | +0.83 |
Omega ratioGain probability vs. loss probability | 1.37 | 1.27 | +0.10 |
Calmar ratioReturn relative to maximum drawdown | 5.74 | 2.62 | +3.13 |
Martin ratioReturn relative to average drawdown | 17.50 | 7.37 | +10.14 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| SBIO | PBE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.30 | 1.55 | +0.75 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.08 | 0.13 | -0.05 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.24 | 0.30 | -0.06 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.21 | 0.32 | -0.11 |
Drawdowns
SBIO vs. PBE - Drawdown Comparison
The maximum SBIO drawdown since its inception was -63.06%, which is greater than PBE's maximum drawdown of -45.69%. Use the drawdown chart below to compare losses from any high point for SBIO and PBE.
Loading charts...
Drawdown Indicators
| SBIO | PBE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -63.06% | -45.69% | -17.37% |
Max Drawdown (1Y)Largest decline over 1 year | -12.66% | -11.73% | -0.93% |
Max Drawdown (3Y)Largest decline over 3 years | -42.44% | -22.43% | -20.01% |
Max Drawdown (5Y)Largest decline over 5 years | -53.10% | -34.71% | -18.39% |
Max Drawdown (10Y)Largest decline over 10 years | -63.06% | -37.84% | -25.22% |
Current DrawdownCurrent decline from peak | -17.95% | -5.55% | -12.40% |
Average DrawdownAverage peak-to-trough decline | -28.45% | -16.24% | -12.21% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.15% | 4.17% | -0.02% |
Volatility
SBIO vs. PBE - Volatility Comparison
ALPS Medical Breakthroughs ETF (SBIO) has a higher volatility of 9.94% compared to Invesco Dynamic Biotechnology & Genome ETF (PBE) at 5.33%. This indicates that SBIO's price experiences larger fluctuations and is considered to be riskier than PBE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SBIO | PBE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.94% | 5.33% | +4.61% |
Volatility (6M)Calculated over the trailing 6-month period | 22.86% | 13.30% | +9.56% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.55% | 18.67% | +10.88% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.55% | 22.52% | +11.03% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 33.18% | 24.91% | +8.27% |
SBIO vs. PBE - Expense Ratio Comparison
SBIO has a 0.50% expense ratio, which is lower than PBE's 0.59% expense ratio.
Dividends
SBIO vs. PBE - Dividend Comparison
SBIO has not paid dividends to shareholders, while PBE's dividend yield for the trailing twelve months is around 1.07%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
PBE Invesco Dynamic Biotechnology & Genome ETF | 1.07% | 1.00% | 0.05% | 0.02% | 0.00% | 0.00% | 0.04% | 0.00% | 0.00% | 0.57% | 0.38% | 1.12% |
SBIO ALPS Medical Breakthroughs ETF | 0.00% | 0.00% | 3.55% | 0.22% | 0.00% | 0.00% | 0.00% | 0.04% | 2.79% | 1.77% | 0.00% | 0.00% |
Frequently Asked Questions
SBIO and PBE have a correlation of 0.70, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SBIO has higher volatility (9.94%) compared to PBE (5.33%). In terms of maximum drawdown, SBIO dropped -63.06% vs PBE's -45.69%.
On 10-year performance, SBIO leads with 7.86% vs 7.34% for PBE. On fees, SBIO is cheaper at 0.50% per year. On volatility, PBE has been the lower-risk option at 5.33%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, SBIO has performed better with a 7.86% return vs 7.34%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
SBIO is cheaper with a 0.50% expense ratio, compared with 0.59% for PBE.
PBE has the higher dividend yield at 1.07%, compared with 0.00% for SBIO.
SBIO tracks S-Network Medical Breakthroughs Index, while PBE tracks Dynamic Biotech & Genome Intellidex Index (AMEX). They also come from different issuers: SS&C and Invesco. Their fees differ too: 0.50% for SBIO and 0.59% for PBE.
SBIO currently has the higher Sharpe Ratio (2.30 vs 1.55), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SBIO and PBE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer